Related Experiment Video

Updated: Jun 21, 2026

Pulse-Wave Velocity, Flow-Mediated Dilation, and Carotid Intima-Media Thickness to Assess Cardiovascular Risk in Population with Metabolic Syndrome
06:04

Pulse-Wave Velocity, Flow-Mediated Dilation, and Carotid Intima-Media Thickness to Assess Cardiovascular Risk in Population with Metabolic Syndrome

Published on: September 27, 2024

CHD risk equivalents and the metabolic syndrome. Trial evidence supports aggressive management

Paul D Thompson1

  • 1Preventive Cardiology and Cardiovascular Research, Hartford Hospital, Hartford, CT 06102, USA. pthomps@harthosp.org

Postgraduate Medicine
|August 12, 2009
PubMed

Insights

Updated guidelines emphasize intensive cholesterol management for coronary heart disease (CHD) patients. Conditions like diabetes and metabolic syndrome also require aggressive lifestyle changes and drug therapy to prevent complications.

Area of Science:

  • Cardiology
  • Public Health

Background:

  • National Cholesterol Education Program's 2001 Adult Treatment Panel III (ATP III) guidelines highlight low-density lipoprotein cholesterol (LDL-C) management in coronary heart disease (CHD).
  • Diabetes, peripheral arterial disease, abdominal aortic aneurysm, and symptomatic carotid artery disease are recognized as CHD risk equivalents.
  • Metabolic syndrome is identified as a secondary target for treatment.

Purpose of the Study:

  • To reaffirm the importance of intensive LDL-C management in patients with established CHD.
  • To outline therapeutic strategies for CHD risk equivalents and metabolic syndrome.

Main Methods:

  • Adherence to updated ATP III guidelines.
  • Implementation of intensive therapeutic lifestyle changes.
  • Initiation of LDL-C-lowering drug therapy, typically with statins.

Main Results:

  • Intensive management of LDL-C is crucial for patients with established CHD.
  • Aggressive lifestyle changes and drug therapy are necessary for CHD risk equivalents to prevent morbidity and mortality.
  • Statin therapy is the primary pharmacological approach, with adjustments or additions (fibrate, niacin) if goals are unmet.

Conclusions:

  • Updated guidelines reinforce the critical role of intensive LDL-C reduction in CHD management.
  • CHD risk equivalents and metabolic syndrome necessitate proactive and intensive treatment strategies.
  • Pharmacological interventions, primarily statins, are essential, with potential escalation to achieve lipid goals.

Related Concept Videos

Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
Cholesterol: Significance and Regulation01:29

Cholesterol: Significance and Regulation

Although not a source of energy, cholesterol plays a significant role as a foundational structure for bile salts, steroid hormones, and vitamin D, as well as being a crucial component of plasma membranes. Approximately 15% of blood cholesterol is derived from our diet, with the remainder synthesized from acetyl CoA by the liver and intestines. Cholesterol is eliminated from the body through its conversion into bile salts, which are eventually discarded in the feces.
Considering cholesterol and...
Diabetes: Management and Pharmacotherapy01:15

Diabetes: Management and Pharmacotherapy

The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...